- Medicin, lægemidler
- Medicinsk forskning
- Sundhed, sundhedsvæsen, lægemidler
- Sundhedspleje, sundhedsvæsen
2012-07-03 09:36 Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
2012-06-29 13:22 Elvitegravir Also a Component of Quad Single Tablet Regimen, Currently Under Regulatory Review for Patients New to Therapy
2012-04-11 08:54 -- Viread Now Available in an Oral Powder and Three Lower-Strength Tablets --
2012-04-02 14:50 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults, submitted on November 24, 2011, has been validated by the European Medicines Agency (EMA).
2012-03-26 10:21 - If Approved, Product Would Represent First Antiretroviral Indicated to Reduce Risk of HIV Infection in Adults -
2012-03-26 10:19 - Company to Submit U.S. Regulatory Filing for Elvitegravir in Second Quarter of 2012 -
2012-03-20 10:16 - Gilead's $8 Million Donation of VL Treatment AmBisome(R) Will Reach 50,000 People in Resource-Limited Countries -
2012-03-20 10:14 - Cobicistat is a Component of Company's Quad Single-Tablet Regimen, Currently Being Reviewed by U.S. FDA -
2012-03-12 15:52 -- Quad Currently Under Review for Marketing Approval by U.S. and European Regulatory Agencies --
2012-03-12 15:34 - Accelerates Development of All-Oral Regimen for the Treatment of HCV - - Leverages Gilead's Infrastructure and Expertise in Antiviral Drug Development, Manufacturing and Commercialization -
2012-03-12 15:32 Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ(R) (atazanavir sulfate) and Gilead's cobicistat.